What is CD138 used for in a lymphoma test?
CD138, also known as Syndecan-1, is a protein that is commonly used as a marker in lymphoma tests. It is present on the surface of plasma cells, which are a type of white blood cell responsible for producing antibodies. In lymphoma, there may be an abnormal proliferation of plasma cells, leading to the formation of malignant tumors.
CD138 helps to identify these malignant plasma cells and is often used in conjunction with other markers to diagnose and classify different types of lymphoma. It is also useful for monitoring disease progression and response to treatment. Overall, the use of CD138 in lymphoma testing helps to improve accuracy and provide more targeted treatment options for patients.
What is the purpose of a CD138 (Syndecan-, lymphoma test?
CD138, also known as Syndecan-1, is a cell surface protein that is often used as a marker for identifying plasma cells. In the context of lymphoma, CD138 testing can be used to distinguish between different subtypes of lymphoma based on the presence or absence of plasma cell markers.
For example, some types of lymphoma, such as multiple myeloma and plasmacytoma, are derived from plasma cells and typically express high levels of CD138. On the other hand, other types of lymphoma, such as follicular lymphoma and mantle cell lymphoma, typically do not express CD138.
Therefore, CD138 testing can be a useful tool for pathologists and oncologists in diagnosing and classifying different types of lymphoma, which in turn can help determine the most appropriate treatment options for patients.
Who should consider getting a CD138 (Syndecan-, lymphoma test?
Individuals who have been diagnosed with lymphoma or are experiencing symptoms such as enlarged lymph nodes, fatigue, unexplained weight loss, night sweats, and fever should consider getting a CD138 (Syndecan-) lymphoma test. This test is used to detect the presence of CD138, a protein found on the surface of plasma cells, which can be used to diagnose different types of lymphoma. Additionally, individuals who have a family history of lymphoma or other cancers may also consider getting this test as part of routine screening or genetic testing. It is important to consult with a healthcare provider to determine if a CD138 lymphoma test is right for you.
How does CD138 (Syndecan) Lymphoma Testing help in diagnosis?
CD138, also known as Syndecan, is a protein that is typically found on the surface of plasma cells in the body. In cases of lymphoma, the presence or absence of CD138 on the tumor cells can provide valuable information for diagnosis and treatment.
CD138 Lymphoma Testing involves taking a sample of the tumor tissue and examining it under a microscope to determine the presence or absence of CD138 on the surface of the tumor cells. If CD138 is present, it can help differentiate between different types of lymphoma, as well as potentially identify the stage and severity of the cancer.
CD138 testing can also be used to monitor the effectiveness of treatment, as changes in CD138 expression can indicate whether the treatment is working or not. This information can help doctors adjust treatment plans and make more informed decisions about patient care.
Overall, CD138 Lymphoma Testing is a valuable tool in the diagnosis and treatment of lymphoma, providing important information about the nature and progression of the cancer and helping doctors make informed decisions about patient care.
What is the procedure for the CD138 (Syndecan-) Lymphoma Test in ?
The CD138 (Syndecan-) Lymphoma Test is a clinical test that is used to diagnose various types of hematological malignancies, such as lymphomas and multiple myelomas. This test requires a bone marrow biopsy or a lung biopsy, depending on the suspected location of the malignancy.
In , the procedure for the CD138 (Syndecan-) Lymphoma Test is carried out by specialized clinics and hospitals that have the necessary equipment and expertise to perform the test. The test involves the use of Next Generation Sequencing (NGS) technology to analyze the DNA and RNA of the malignant cells, which helps in identifying the specific type of lymphoma or myeloma.
To undergo the CD138 (Syndecan-) Lymphoma Test in , patients need to consult with a hematologist or oncologist who will evaluate their medical history and symptoms and recommend the test if needed. The procedure involves the collection of a bone marrow or lung biopsy sample, which is then sent to a specialized laboratory for analysis.
Once the results are obtained, the hematologist or oncologist will interpret the findings and correlate them with the patient's clinical and radiological data to make an accurate diagnosis and develop an appropriate treatment plan.
In summary, the CD138 (Syndecan-) Lymphoma Test is a specialized clinical test that requires a bone marrow or lung biopsy and Next Generation Sequencing technology to diagnose hematological malignancies. Patients in can undergo this test CD138 (Syndecan-) Lymphoma Test is a valuable tool for diagnosing and monitoring hematological malignancies. The procedure in involves specialized clinics and hospitals that perform bone marrow or lung biopsies and use Next Generation Sequencing technology for analysis. The results are interpreted by a hematologist or oncologist, who will then correlate them with the patient's clinical and radiological data to develop an appropriate treatment plan. This clinical test helps doctors make informed decisions about patient care and improve the chances of successful treatment outcomes.
Description- CD138 is a transmembrane heparin sulphate glycoprotein that is expressed by normal lymphoid cells, IgG plasma cells, pre-B cells, and immature B cells. It differentiates squamous cell carcinomas, postgerminal-center B cells, and plasma cells and is expressed in plasma cells of CLL, plasmacytoid lymphomas, and myelomas
TAT: 3-5 days
Collect - tissue /or cell
Specimen Preparation- formal fix (10 % neutral buffered formalin) and paraffin enter specimen (FFPE specimens square measure needed). shield paraffin block or slides from uncontrolled heat. Transport tissue block or five unstained (3-micron thick sections), charged slides during a tissue transport kit. (Min: a pair of slides). If causing precut slides, don't over heat it.
Storage/Transport Temperature- At temperature or cold. Transport it in cooled instrumentation throughout weather.
Unacceptable conditions- i) Specimens submitted with non-marked/tagged tissue sort square measure rejected.
ii) Depleted specimens aren't tested.
Stability- i) Ambient: Indefinitely;
ii) Refrigerated: Indefinitely;
iii) Frozen: Unacceptable